



## Medical Exemption (Contraindication or Deferral)

For a medical exemption, the individual must provide proof of a valid contraindication or deferral. A licensed physician must complete the information requested herein before submitting to the Curling Canada Medical committee for approval. For reference, see next page for contraindication and deferrals for both vaccine types.

<b>Patient/ Individual name:</b>
<b>Physician name:</b>
<b>Physician contact number:</b>
<b>Physician license number:</b>
<b>Rationale for contraindication or deferral:</b>
<b>Physician signature:</b>

<b>Valid Contraindication</b>	History of an anaphylactic reaction to components of both mRNA and adenovirus vector vaccine (i.e., polyethylene glycol and polysorbate 80)
<b>Valid Deferrals</b>	Receipt of anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma for treatment or prevention of COVID-19 (except tocilizumab or sarilumab) – defer for at least 90 days
	Diagnosis of Guillain-Barré Syndrome after a previous vaccination. Copy of neurologic consult must be provided
	Diagnosis of Multisystem Inflammatory Syndrome – defer until fully recovered from illness and for 90 days after the date of diagnosis
	Physician-diagnosed myocarditis or pericarditis following the first dose with no other cause identified – defer until further information about the risk of recurrence is available
	Suspected hypersensitivity or non-anaphylactic allergy to COVID-19 vaccine components - consultation with an allergist is advised
	Serious adverse event following first dose of vaccine awaiting recommendation for further vaccination by the Medical Health Officer
<b>Invalid contraindications</b>	History of an anaphylactic reaction to a previous dose of mRNA or adenovirus vector vaccine. Such individuals may receive their 2nd dose using vaccine of the different type.
	History of an anaphylactic reaction to any component of one type of vaccine. Such individuals may receive vaccine of the different type.
	History of thrombosis with thrombocytopenia following a previous dose of an adenovirus vector COVID-19 vaccine. Such individuals may receive mRNA vaccine.
	History of capillary leak syndrome. Such individuals may receive mRNA vaccine.
	History of cerebral venous sinus thrombosis (CVST) with thrombocytopenia, unrelated to adenovirus vector COVID-19 vaccination, or heparin induced thrombocytopenia (HIT). Such individuals may receive mRNA vaccine.

For further guidance regarding the approach to individuals with allergies and COVID-19 vaccines, see Vander Leek TK, Chan ES, Connors L et al. COVID-19 vaccine testing & administration guidance for allergists/immunologists from the Canadian Society of Allergy and Clinical Immunology (CSACI). Allergy Asthma Clin Immunol. 2021 Mar 15;17(1):29. doi: 10.1186/s13223-021-00529-2. PMID: 33722299; PMCID: PMC7957441.

<https://csaci.ca/wp-content/uploads/2021/03/NEW-INFORMATION-TIMS-ARTICLE-MAR2021.pdf>

Corresponding patient resource: <https://csaci.ca/covid-19-vaccines-faq/>